The appointees shall work in Hong Kong Science and Technology Park. Experienced in animal handling techniqueĪpplicants should have a good command of written and spoken English, strong communication skills, and be self-motivated, hardworking and able to work well in an interdisciplinary team.Experienced in mouse models, xenograft models and biobanking.

Specialised research interest in multi-omics profiling, bioinformatics, cancer metabolism, medicinal chemistry, and drug discovery.

Experienced in molecular biology laboratory techniques (including cloning) and handling mammalian cell culture.

Understanding and/or experience in CRISPR/Cas9 technology, high-throughput screening techniques, next generation sequencing, and single cell sequencing technologies.

Possess a demonstrated track record of publishing academic research papers.

A strong background in other fields of biomedical sciences including Cancer Biology, Genomics, Metabolomics, Bioinformatics, Single Cell Technology or Medicinal Chemistry is highly desirable. Candidates will also be involved in the development of novel compounds against established targets.Īpplicants with strong research background in Molecular Biology is required. The successful candidate will work in close collaboration with the principal investigator’s scientific teams at the Centre of Oncology and Immunology and the Princess Margaret Cancer Centre to systemically decipher the synthetic lethal interactions with mutations that are commonly found in myeloid malignancies (e.g, acute myeloid leukemia) using state-of-art functional genomics tools.Ĭandidates are expected to perform collaborative research projects in the discovery of synthetic lethal interactions using large scale functional genomics approaches and novel animal models. Steven Chan as part of a collaborative program between the University of Hong Kong and the University Health Network/Princess Margaret Cancer Centre (Canada). The position will focus on acute myeloid leukemia under the direction of Dr. Success in this venture will address pressing unmet medical needs and establish Hong Kong as a leading hub of innovative anti-cancer and immuno-oncology drug development. The ultimate goal is to develop therapeutics against these targets and to conduct clinic al trials evaluating these drugs along with biomarkers with an eye to their eventual commercialization worldwide. The long-term objective of the Centre for Oncology and Immunology is to employ novel functional screens, animal and cell models including organoids, immuno-oncology approach, as well as advanced genomic and proteomic techniques down to single cell resolution to identify novel “druggable” cancer targets for hard-to-treat malignancies.

Doctor Who by Steve Cole